AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
GlobalData on MSN13d
EC approves AstraZeneca’s Fasenra for EGPA treatmentFasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback